Medicenna Therapeutics Corp.
NASDAQ:MDNA
0.16 (USD) • At close September 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Medicenna Therapeutics Corp. |
Symbool | MDNA |
Munteenheid | USD |
Prijs | 0.157 |
Beurswaarde | 0 |
Dividendpercentage | 0% |
52-weken bereik | 0.151 - 0.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Fahar Merchant Ph.D. |
Website | https://www.medicenna.com |
An error occurred while fetching data.
Over Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)